MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

MoonLake to tap into Komodo’s technology and real-world data to unlock the full potential of its next-gen Nanobody therapy

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA), two underdiagnosed diseases with significant unmet patient needs.

Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams. Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.

Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors. Komodo’s data-driven intelligence is expected to be a critical tool as we work towards commercialization and delivering transformative therapies to patients.”

Recent research underscores the challenges life sciences companies face generating data-driven intelligence that can support decision-making across the product life cycle. On average, it takes seven months to identify and integrate data sources before teams can even begin to generate insights.

Using Komodo’s software applications and Healthcare Map, MoonLake was able to identify important findings, presented at its R&D day last month, related to the HS market. The real-world analysis of the U.S. patient population revealed that between 2016 and 2023, two million unique patients were diagnosed and treated for HS, not including undiagnosed and untreated patients. The data also revealed that, on average, 240,000 net new patients get diagnosed and treated each year. This data helps to substantiate the prevalence of HS as ~2% as stated in the literature. The real-world insights from Komodo helped validate a future HS market size projected to exceed $10B by 2035. Today, there is a notably low penetration of current biologics (around 3%) and a high dropout rate from these current biologics within the first year (median treatment duration in a real world setting of 11 months). Furthermore, these insights shed light on the challenges of care and that individuals living with HS are being lost in their treatment journey. Over 50-60% of patients are on long-term antibiotics, and many are concurrently prescribed steroids and/or opioids. This real-world perspective substantiates MoonLake’s market size estimates and highlights the need for more effective therapies.